3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 2
1
Status
Completed
9
Recruiting
8
Unknown
3
Terminated
2
Active not recruiting
2
Withdrawn
1
Approved for marketing
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Tumor-Agnostic
2
Conditions
Prostatic Neoplasms
9
Ovarian Neoplasms
8
Breast Neoplasms
7
Triple Negative Breast Neoplasms
3
Pancreatic Neoplasms
3
Neoplasms
2
Neoplasm Metastasis
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Fallopian Tube Neoplasms
2
Endometrial Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Advanced Solid Tumor
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thrombocytosis
1
Solid Tumors
1
Prostatic Neoplasms, Castration-Resistant
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Ovarian Neoplasm Epithelial
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Lung Neoplasms
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
1
Interventions
Gemcitabine
34
pembrolizumab
26
Paclitaxel
21
Cyclophosphamide
21
Docetaxel
20
Carboplatin
20
Irinotecan
19
Capecitabine
19
Fluorouracil
17
Bevacizumab
15
Dexamethasone
14
fludarabine
13
Oxaliplatin
13
Leucovorin
13
Blood Specimen Collection
13
Everolimus
12
Cetuximab
12
Ipilimumab
11
Erlotinib Hydrochloride
11
Rituximab
10
Pemetrexed
10
Cisplatin
10
venetoclax
9
Temozolomide
9
Sunitinib
9
Nivolumab
9
Trastuzumab
8
Interleukin-2
8
aldesleukin
7
Epoetin Alfa
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Terminated
×
Neoplasms
×
olaparib
×
Clear all
NCT04801966
2023-05-10
TAILOR
Peter MacCallum Cancer Centre, Australia
Phase NA
Terminated
3 enrolled
NCT02576444
2022-12-28
OLAPCO
Yale University
Phase 2
Terminated
67 enrolled
10 charts